Display options
Cite
Wright CE, Robertson AD, Whorlow SL, et al. Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol. 2000;131(7):1325-36doi: 10.1038/sj.bjp.0703701.
Wright, C. E., Robertson, A. D., Whorlow, S. L., & Angus, J. A. (2000). Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. British journal of pharmacology, 131(7), 1325-36. https://doi.org/10.1038/sj.bjp.0703701
Wright, C E, et al. "Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays." British journal of pharmacology vol. 131,7 (2000): 1325-36. doi: https://doi.org/10.1038/sj.bjp.0703701
Wright CE, Robertson AD, Whorlow SL, Angus JA. Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol. 2000 Dec;131(7):1325-36. doi: 10.1038/sj.bjp.0703701. PMID: 11090104; PMCID: PMC1572459.
Copy Download .nbib Format: NLM
Share it on

Br J Pharmacol. 2000 Dec;131(7):1325-36. doi: 10.1038/sj.bjp.0703701.

Cardiovascular and autonomic effects of omega-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays.

British journal of pharmacology

C E Wright, A D Robertson, S L Whorlow, J A Angus

Affiliations

  1. Department of Pharmacology, The University of Melbourne, Victoria 3010, Australia. [email protected]

PMID: 11090104 PMCID: PMC1572459 DOI: 10.1038/sj.bjp.0703701

Abstract

1. The effects of a novel N-type voltage-operated calcium channel antagonist, omega-conotoxin CVID, were compared with omega-conotoxin MVIIA on sympathetic-evoked activation of right atria (RA), small mesenteric arteries (MA) and vasa deferentia (VD) isolated from the rat. Their effects were also compared on blood pressure and cardiovascular reflexes in conscious rabbits. 2. The pIC(50) values for MVIIA and CVID, respectively, for inhibiting sympathetic-evoked responses were equivalent in RA (8.7 and 8.7) and VD (9.0 and 8.7); however, in MA the values were 8.4 and 7.7. The cardiac to vascular (RA/MA) potency ratios, antilog (plog RA - plog MA), for MVIIA and CVID were 2 and 10. The offset rates for CVID and MVIIA were rapid, and peptide reapplication caused rapid onset of blockade, suggesting limited desensitization. 3. In the conscious rabbit, CVID and MVIIA (100 microg kg(-1) i.v.) caused a similar fall in blood pressure and a tachycardia that rapidly reached maximum. Both peptides decreased the vagal- and sympathetic-mediated components of the baroreflex, but had no effect on the vagal nasopharyngeal reflex. The orthostatic reflex to 90 degrees tilt was blocked by MVIIA with sustained postural hypotension for > or = 90 min after administration. In contrast, CVID caused postural hypotension at 30 min which recovered rapidly. 4. Neither CVID nor MVIIA (3 microg kg(-1) i.t.) significantly altered cardiovascular variables or autonomic reflexes. 5. In conclusion, CVID appears to be relatively weak at inhibiting the reflex response to tilt consistent with its weaker inhibition of rat mesenteric artery constriction to perivascular nerve stimulation. This may point to subtype N-type calcium channel selectivity.

References

  1. J Biol Chem. 1997 May 2;272(18):12014-23 - PubMed
  2. J Cardiovasc Pharmacol. 1997 Sep;30(3):400-3 - PubMed
  3. Drug Discov Today. 2000 Mar;5(3):98-106 - PubMed
  4. Nature. 1987 May 14-20;327(6118):158-60 - PubMed
  5. Eur J Biochem. 1999 Jun;262(2):447-55 - PubMed
  6. J Physiol. 1988 Sep;403:495-510 - PubMed
  7. J Cardiovasc Pharmacol. 1992;20(5):756-64 - PubMed
  8. Physiol Behav. 1976 Dec;17(6):1031-6 - PubMed
  9. Clin Exp Pharmacol Physiol. 1995 Oct;22(10):711-6 - PubMed
  10. Clin Exp Pharmacol Physiol. 1994 Nov;21(11):865-73 - PubMed
  11. Circ Res. 1977 Jul;41(1):19-26 - PubMed
  12. Pain. 2000 Mar;85(1-2):291-6 - PubMed
  13. J Mol Recognit. 2000 Mar-Apr;13(2):55-70 - PubMed
  14. Br J Pharmacol. 1992 Oct;107(2):347-51 - PubMed
  15. J Cardiovasc Pharmacol. 1995 Mar;25(3):459-68 - PubMed
  16. Aust J Exp Biol Med Sci. 1974 Feb;52(1):111-26 - PubMed
  17. J Cardiovasc Pharmacol. 1990 Oct;16(4):675-80 - PubMed
  18. Br J Pharmacol. 1996 Sep;119(1):49-56 - PubMed
  19. Clin J Pain. 1997 Sep;13(3):256-9 - PubMed
  20. Cardiovasc Res. 1994 Mar;28(3):303-11 - PubMed
  21. J Hypertens. 1983 Aug;1(2):183-90 - PubMed
  22. J Hypertens. 2000 Jan;18(1):65-73 - PubMed
  23. Hypertension. 1987 Feb;9(2):122-31 - PubMed
  24. J Biol Chem. 2000 Nov 10;275(45):35335-44 - PubMed
  25. Clin Exp Pharmacol Physiol. 1992 Aug;19(8):587-97 - PubMed
  26. J Cardiovasc Pharmacol. 1997 Sep;30(3):392-9 - PubMed
  27. J Auton Nerv Syst. 1987 Dec;21(2-3):203-13 - PubMed
  28. Eur J Pharmacol. 2000 Jan 24;388(1):89-95 - PubMed
  29. J Cardiovasc Pharmacol. 1998 Dec;32(6):951-61 - PubMed

Substances

MeSH terms

Publication Types